WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced the launch of Revvity Transcribe AI, an innovative optical character recognition (OCR) service designed to convert ...
Combination of Revvity’s proprietary Pin-point platform and Profluent’s AI-engineered proteins created to inspire accelerated development of novel gene editing therapies This new Pin-point ...
WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, ...
Revvity, Inc. RVTY recently collaborated with Element Biosciences, Inc. The tie-up is aimed at introducing workflow solutions that can save the time and effort needed for the genomic analysis of ...
Revvity emerged from the life sciences and diagnostics business of PerkinElmer (MA, USA) in May 2023 when the company divested its food, applied and enterprise services businesses. These businesses ...
Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback